II. Epidemiology
- Prevalence prostate Cancer Survivors in U.S.: 3 Million (2014)
-
Incidence new Prostate Cancers per year: 233,000 (2014)
- Most Prostate Cancers are diagnosed as local or regional disease
- Most patients with newly diagnosed Prostate Cancer will survivor decades
III. Complications
-
General concerns
- See Cancer Survivor Care
- Address Major Depression or Anxiety Disorder (including Adjustment Disorder)
- Address concerns of family members supporting the patient
- Encourage healthy lifestyle (Tobacco Cessation, weight management, nutrition, aerobic activity)
-
Prostate Cancer recurrence
- Treated initially with androgen suppression (resistance inevitably develops)
- Later treatment with Radiotherapy or Chemotherapy
- Androgen suppression adverse effects
- Osteopenia or Osteoporosis
- See Osteoporosis Prevention
- Obtain Bone Mineral Density (DEXA Scan) and calculate FRAX Score before initiating
- Hot Flashes (40% of patients)
- Symptoms may persist for years after completion of androgen suppression
- See Hot Flashes for management strategies
- Consider low dose Paroxetine, Venlafaxine, Gabapentin
- Normochromic Normocytic Anemia
- Erectile Dysfunction
- Fatigue
- Gynecomastia
- Weight gain (with risk of Metabolic Syndrome)
- Loss of body hair
- Dry Eyes
- Venous Thromboembolism
- Osteopenia or Osteoporosis
-
Radiotherapy adverse effects
- Radiation Proctitis
- Inital symptoms of Diarrhea, Rectal Bleeding, Flatulence
- Later findings include Rectal Fistulas or ulceration, fecal urgency, frequency, Stool Incontinence
- Start with hydration and Stool Softeners
- Consider rectal steroids (e.g. Hydrocortisone) or antiinflammatories (e.g. Mesalamine)
- Urinary Dysfunction
- Urinary Incontinence (Stress Incontinence, Urge Incontinence)
- Urethral Stricture
- Urinary tract fistulas
- Urinary obstructive symptoms similar to BPH
- Other urinary symptoms (urinary urgency or frequency, dribbling, Nocturia)
- May present in similar fashion to Urinary Tract Infection
- See management strategies below under Prostatectomy adverse effects
- Erectile Dysfunction (72% at five years)
- Erectile Dysfunction onset may be delayed 6 to 36 months from treatment
- May respond to standard Erectile Dysfunction methods (e.g. PDE5 Inhibitors such as Viagra)
- Secondary cancer (Rectal cancer, Bladder Cancer)
- Occurs in 1 in 220-290
- Refer for Hematuria (routine Urinalysis screening not recommended)
- Radiation Proctitis
-
Prostatectomy adverse effects
- Erectile Dysfunction (76% at five years)
- May respond to standard Erectile Dysfunction methods (e.g. PDE5 Inhibitors such as Viagra)
- Urinary Dysfunction
- Urethral Stricture
- Other urinary symptoms (urinary urgency or frequency, dribbling, Nocturia)
- Urinary Incontinence (esp. Stress Incontinence)
- Stress Incontinence improves over first year, and typically resolves
- Urge Incontinence responds to standard treatments
- Consider Pelvic Floor Exercises, timed voiding at regular intervals
- Consider Anticholinergic Medications (e.g. Oxybutynin)
- Invasive methods are available (e.g. Collagen, slings)
- Erectile Dysfunction (76% at five years)
IV. Monitoring: General Protocol after Prostate Cancer Diagnosis
- See Active Surveillance of Prostate Cancer (non-treatment approach)
- Prostate Specific Antigen (PSA) as below
- Digital Rectal Exam yearly (may be omitted if PSA remains undetectable)
- Clinical examination every 6 months for 5 years
- Focus area on exam
- Bladder Cancer (new second tumor)
- Erectile Dysfunction
- Stool or Urinary Incontinence
- Radiation Proctitis
- Major Depression
- Quality of life assessment tool
- Expanded Prostate Cancer index composite for clinical practice (EPIC-CP)
V. Monitoring: Prostate Specific Antigen (PSA) after Prostate Cancer Diagnosis
- Frequency of PSA Testing
- Initial: PSA every 6 months (to 12 months) for 5 years
- After fifth year: PSA every year
- PSA Levels after Radical Prostatectomy
- PSA <0.03 ng/ml within 2 months of Prostatectomy
- Refer if PSA becomes detectable again
- PSA rise >2 ng/ml/year suggests high grade lesion
- PSA Levels after Radiotherapy
- PSA falls gradually to under 1 ng/ml by 1 year
- PSA remains under 1 ng/ml unless cancer recurrence
- Repeat PSA in 3 months if PSA increased from previous level (Refer if trending upwards)
- PSA after Androgen Suppression
- PSA falls to <0.05 to 0.1 ng/ml within 8 weeks of starting suppressive therapy
- Co-manage PSA results with oncology or urology
VI. Resources
VII. References
- Mohan (2011) Am Fam Physician 84(4): 413-20 [PubMed]
- Friedman (1996) Postgrad Med 100(3): 125-36 [PubMed]
- Middleton (1996) CA Cancer J Clin 46(4):249-53 [PubMed]
- Naitoh (1998) Am Fam Physician 57(7):1531-9 [PubMed]
- Noonan (2016) Am Fam Physician 93(9): 764-70 [PubMed]
- Porter (1995) CA Cancer J Clin 45(3):165-78 [PubMed]
- Skolarus (2014) CA Cancer J Clin 64(4): 225-49 [PubMed]
- Taub (1996) Postgrad Med 100(3): 139-54 [PubMed]
- Wilbur (2014) Am Fam Physician 91(1):29-36 [PubMed]
- Williams (1996) Postgrad Med 100(3): 105-20 [PubMed]